Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04285671
What this trial is testing

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center 30
Early research (Phase 1)Active Not RecruitingNCT04676477
What this trial is testing

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 246
Not applicableStudy completedNCT01153399
What this trial is testing

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 589
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Early research (Phase 1)Ended earlyNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Testing effectiveness (Phase 2)Looking for participantsNCT07073365
What this trial is testing

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital 70
Early research (Phase 1)Active Not RecruitingNCT04013542
What this trial is testing

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Who this might be right for
ALK Gene RearrangementEGFR Gene MutationLocally Advanced Lung Non-Small Cell Carcinoma+9 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03586453
What this trial is testing

Osimertinib In EGFR Mutant Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Dana-Farber Cancer Institute 30
Early research (Phase 1)Active Not RecruitingNCT02503722
What this trial is testing

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)UnknownNCT01749072
What this trial is testing

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEffects of Chemotherapy
Peking Union Medical College Hospital 120
Testing effectiveness (Phase 2)WithdrawnNCT02347839
What this trial is testing

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Who this might be right for
Lung Cancer
Sun Yat-sen University
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421